Wall Street Zen upgraded shares of Compass Pathways (NASDAQ:CMPS – Free Report) from a sell rating to a hold rating in a research note published on Monday,Wall Street Zen reports.
CMPS has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating on shares of Compass Pathways in a report on Monday, November 9th. Morgan Stanley increased their price objective on shares of Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Jefferies Financial Group reiterated a “buy” rating on shares of Compass Pathways in a research note on Monday, November 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research note on Thursday, October 15th. Finally, Wells Fargo & Company cut their price target on Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.14.
Read Our Latest Research Report on Compass Pathways
Compass Pathways Stock Down 8.2%
Shares of Compass Pathways stock opened at $8.27 on Monday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.50 and a quick ratio of 1.50. Compass Pathways has a 1 year low of $4.88 and a 1 year high of $15.87. The business has a 50-day moving average of $11.79 and a two-hundred day moving average of $10.47. The company has a market capitalization of $1.17 billion, a P/E ratio of -2.37 and a beta of 2.43.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. As a group, equities analysts predict that Compass Pathways will post -0.78 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the stock. Eagle Health Investments LP lifted its position in shares of Compass Pathways by 35.6% during the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock worth $11,394,000 after buying an additional 541,039 shares in the last quarter. Candriam S.C.A. boosted its stake in Compass Pathways by 18.6% in the 3rd quarter. Candriam S.C.A. now owns 1,510,695 shares of the company’s stock worth $18,862,000 after purchasing an additional 236,417 shares during the period. Creek Drive Management Group LLC boosted its position in shares of Compass Pathways by 91.9% in the third quarter. Creek Drive Management Group LLC now owns 1,328,000 shares of the company’s stock valued at $16,520,000 after acquiring an additional 636,000 shares during the period. Orbimed Advisors LLC purchased a new position in shares of Compass Pathways during the 1st quarter valued at $6,363,000. Finally, Affinity Asset Advisors LLC grew its position in Compass Pathways by 454.2% during the first quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company’s stock worth $6,130,000 after buying an additional 908,483 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.
Compass Pathways Company Profile
Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.
Further Reading
- Five stocks we like better than Compass Pathways
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
